180 related articles for article (PubMed ID: 26301416)
1. Low Incidence of Renal Dysfunction among HIV-Infected Patients on a Tenofovir-Based First Line Antiretroviral Treatment Regimen in Myanmar.
Kyaw NT; Harries AD; Chinnakali P; Antierens A; Soe KP; Woodman M; Das M; Shetty S; Zuu MK; Htwe PS; Fernandez M
PLoS One; 2015; 10(8):e0135188. PubMed ID: 26301416
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-naïve individuals in Lilongwe, Malawi.
Johnson DC; Chasela C; Maliwichi M; Mwafongo A; Akinkuotu A; Moses A; Jamieson DJ; Kourtis AP; King CC; van der Horst C; Hosseinipour MC
PLoS One; 2012; 7(7):e41011. PubMed ID: 22848422
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
Quesada PR; Esteban LL; García JR; Sánchez RV; García TM; Alonso-Vega GG; Ferrández JS
Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
[TBL] [Abstract][Full Text] [Related]
4. The effect of Tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis.
Salome T; Kasamba I; Mayanja BN; Kazooba P; Were J; Kaleebu P; Munderi P;
AIDS Res Ther; 2016; 13(1):28. PubMed ID: 27582777
[TBL] [Abstract][Full Text] [Related]
5. Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
Mulenga L; Musonda P; Mwango A; Vinikoor MJ; Davies MA; Mweemba A; Calmy A; Stringer JS; Keiser O; Chi BH; Wandeler G;
Clin Infect Dis; 2014 May; 58(10):1473-80. PubMed ID: 24585558
[TBL] [Abstract][Full Text] [Related]
6. Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.
Huang YS; Chan CK; Tsai MS; Lee KY; Lin SW; Chang SY; Hung CC; Chang SC
J Microbiol Immunol Infect; 2017 Oct; 50(5):595-603. PubMed ID: 26514942
[TBL] [Abstract][Full Text] [Related]
7. Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific.
Tanuma J; Jiamsakul A; Makane A; Avihingsanon A; Ng OT; Kiertiburanakul S; Chaiwarith R; Kumarasamy N; Nguyen KV; Pham TT; Lee MP; Ditangco R; Merati TP; Choi JY; Wong WW; Kamarulzaman A; Yunihastuti E; Sim BL; Ratanasuwan W; Kantipong P; Zhang F; Mustafa M; Saphonn V; Pujari S; Sohn AH;
PLoS One; 2016; 11(8):e0161562. PubMed ID: 27560968
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Tenofovir-Associated Nephrotoxicity Among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals.
LaFleur J; Bress AP; Esker S; Knippenberg K; Crook J; Nyman H; Bedimo R; Tebas P; Rosenblatt L
J Acquir Immune Defic Syndr; 2018 Mar; 77(3):325-330. PubMed ID: 29210830
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors for tenofovir-associated nephrotoxicity among human immunodeficiency virus-infected patients in Korea.
Lee JE; Lee S; Song SH; Kwak IS; Lee SH
Korean J Intern Med; 2019 Mar; 34(2):409-417. PubMed ID: 29020764
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana.
Nartey ET; Tetteh RA; Yankey BA; Mantel-Teeuwisse AK; Leufkens HGM; Dodoo ANO; Lartey M
BMC Res Notes; 2019 Jul; 12(1):445. PubMed ID: 31331365
[TBL] [Abstract][Full Text] [Related]
11. Effect of TDF-containing regimens on creatinine clearance in HIV patients in Namibia with a baseline CrCl <60ml/min; findings and implications.
Kalemeera F; Godman B; Stergachis A; Rennie T
Hosp Pract (1995); 2020 Feb; 48(1):35-40. PubMed ID: 31829065
[No Abstract] [Full Text] [Related]
12. Reversibility of renal dysfunction after discontinuation of tenofovir.
Cha A; Besignano-Long AR; Rothberger N; Shah B
J Am Pharm Assoc (2003); 2016; 56(3):280-3. PubMed ID: 27067552
[TBL] [Abstract][Full Text] [Related]
13. Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir.
Yilma D; Abdissa A; Kæstel P; Tesfaye M; Olsen MF; Girma T; Ritz C; Friis H; Andersen ÅB; Kirk O
BMC Infect Dis; 2020 Aug; 20(1):582. PubMed ID: 32762646
[TBL] [Abstract][Full Text] [Related]
14. Urinary β2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy.
Nishijima T; Kurosawa T; Tanaka N; Kawasaki Y; Kikuchi Y; Oka S; Gatanaga H
AIDS; 2016 Jun; 30(10):1563-71. PubMed ID: 26919734
[TBL] [Abstract][Full Text] [Related]
15. Renal outcomes in patients initiated on tenofovir disoproxil fumarate-based antiretroviral therapy at a community health centre in Malawi.
Chikwapulo B; Ngwira B; Sagno JB; Evans R
Int J STD AIDS; 2018 Jun; 29(7):650-657. PubMed ID: 29334883
[TBL] [Abstract][Full Text] [Related]
16. Renal dysfunction by baseline CD4 cell count in a cohort of adults starting antiretroviral treatment regardless of CD4 count in the HIV Prevention Trials Network 071 [HPTN 071; Population Effect of Antiretroviral Therapy to Reduce HIV Transmission (PopART)] study in South Africa.
Bock P; Nel K; Fatti G; Sloot R; Ford N; Voget J; Gunst C; Grobbelaar N; Louis F; Floyd S; Hayes R; Ayles H; Beyers N; Fidler S;
HIV Med; 2019 Jul; 20(6):392-403. PubMed ID: 30963667
[TBL] [Abstract][Full Text] [Related]
17. Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults.
Agbaji OO; Abah IO; Ebonyi AO; Gimba ZM; Abene EE; Gomerep SS; Falang KD; Anejo-Okopi J; Agaba PA; Ugoagwu PO; Agaba EI; Imade GE; Sagay AS; Okonkwo P; Idoko JA; Kanki PJ
J Int Assoc Provid AIDS Care; 2019; 18():2325958218821963. PubMed ID: 30672363
[TBL] [Abstract][Full Text] [Related]
18. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.
Gupta SK; Anderson AM; Ebrahimi R; Fralich T; Graham H; Scharen-Guivel V; Flaherty JF; Fortin C; Kalayjian RC; Rachlis A; Wyatt CM
PLoS One; 2014; 9(3):e92717. PubMed ID: 24651857
[TBL] [Abstract][Full Text] [Related]
19. Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial.
Baltrusaitis K; Makanani B; Tierney C; Fowler MG; Moodley D; Theron G; Nyakudya LH; Tomu M; Fairlie L; George K; Heckman B; Knowles K; Browning R; Siberry GK; Taha TE; Stranix-Chibanda L;
BMC Infect Dis; 2022 Jul; 22(1):634. PubMed ID: 35858874
[TBL] [Abstract][Full Text] [Related]
20. Effects of long-term exposure to tenofovir disoproxil fumarate-containing antiretroviral therapy on renal function in HIV-positive Chinese patients.
Tan Q; He YH; Yang TT; Yan DM; Wang Y; Zhao X; Liu HX; He SH; Zhou ZH
J Microbiol Immunol Infect; 2019 Oct; 52(5):710-719. PubMed ID: 31427111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
